Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.43 |
| ▸ | METAP1 | P53582 | 2/20 | 0.36 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665386 | 1.00 | FAAH (0.43) | FAAHMETAP1SLC15A1GRIK1SLC1A3 | |
| SCHEMBL20854298 | 1.00 | FAAH (0.43) | FAAHMETAP1SLC15A1GRIK1SLC1A3 | |
| SCHEMBL16554070 | 1.00 | FAAH (0.43) | FAAHMETAP1SLC15A1GRIK1SLC1A3 | |
| SCHEMBL16554069 | 1.00 | FAAH (0.43) | FAAHMETAP1SLC15A1GRIK1SLC1A3 | |
| SCHEMBL16554067 | 1.00 | FAAH (0.43) | FAAHMETAP1SLC15A1GRIK1SLC1A3 | |
| SCHEMBL16554242 | 1.00 | FAAH (0.43) | FAAHMETAP1SLC15A1GRIK1SLC1A3 | |
| SCHEMBL14296417 | 0.86 | FAAH (0.46) | FAAHCNR1CNR2CHRM1CHRM3 | |
| SCHEMBL14296416 | 0.86 | FAAH (0.46) | FAAHCNR1CNR2CHRM1CHRM3 | |
| SCHEMBL880134 | 0.86 | FAAH (0.46) | FAAHCNR1CNR2CHRM1CHRM3 | |
| SCHEMBL15796363 | 0.84 | FAAH (0.63) | FAAHGRIK1GRIK2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2022-09-20 | — | — | US | disclosed |
| EP-3572410-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-11-03 | — | — | US | disclosed |
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-05-19 | — | — | US | disclosed |
| EP-3186244-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2020-04-22 | — | — | EP | disclosed |
| EP-3572410-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | Medivir Aktiebolag (SE) | 2019-11-27 | — | — | EP | disclosed |
| US-9540411-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2017-01-10 | — | — | US | disclosed |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-9481703-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2016-11-01 | — | — | US | disclosed |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-09-22 | — | — | US | disclosed |
| EP-3057976-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-08-24 | — | — | EP | disclosed |
| EP-3041855-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016030335-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2016-03-03 | — | — | WO | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| WO-2015056213-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015034420-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | FAAH 3921/4885METAP1 4420/4885SLC15A1 1540/4885 |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | FAAH 2033/4885METAP1 343/4885SLC15A1 2164/4885 |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | FAAH 3882/4885METAP1 4432/4885SLC15A1 1587/4885 |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | FAAH 3921/4885METAP1 4420/4885SLC15A1 1540/4885 |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | FAAH 2033/4885METAP1 343/4885SLC15A1 2164/4885 |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | FAAH 2033/4885METAP1 343/4885SLC15A1 2164/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | FAAH 3921/4885METAP1 4420/4885SLC15A1 1540/4885 |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | FAAH 3921/4885METAP1 4420/4885SLC15A1 1540/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | FAAH 3921/4885METAP1 4420/4885SLC15A1 1540/4885 |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | FAAH 3921/4885METAP1 4420/4885SLC15A1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.